Ruxolitinib vs Allogeneic SCT for Patients With Myelofibrosis According to Donor Availability

NCT03333187 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

87

Enrollment

OTHER

Sponsor class

Conditions

Bone Marrow Fibrosis

Interventions

PROCEDURE: Allogeneic stem cell transplantation
DRUG: Ruxolitinib continuous therapy

Sponsor

Universitätsklinikum Hamburg-Eppendorf

Collaborators

[object Object]
[object Object]